Evaluation Of The Long-term Efficacy Of DAA Drugs In Treating HCV Infected Individuals After Achieving SVR

To explore the long-term efficacy of DAA drugs in treating HCV infected individuals after achieving SVR,clarify the long-term efficacy of the drugs,and provide clinical ideas for further treatment of HCV infected individuals.Method: This study selected 83 patients with hs HCV RNA>12IU/ml who had been treated with oral DAA medication and had been stopped for ≥ 12 months,and were regularly reviewed,among 593 infected individuals who were found to have hs HCV RNA>12IU/ml at the Department of Infectious Diseases at Yan’an University Affiliated Hospital from January 2017 to December 2020.According to clinical symptoms,signs,laboratory tests,and imaging examinations,they were divided into 41 cases of chronic hepatitis C group,22 cases of compensated hepatitis C cirrhosis group,and 20 cases of decompensated hepatitis C cirrhosis group.Collect basic data on the 83 patients mentioned above,including gender,age,observation time,infection pathway,and hs HCV RNA,ALB,ALT,AST,TBil,DBi L,IBi L,AFP,abdominal ultrasound,liver hardness values from the time the patient obtained SVR to the end of observation.By comparing the clinical trial indicators obtained from SVR treatment of HCV infected individuals with DAA drugs and at the end of observation,the long-term efficacy of DAA drugs in achieving SVR in HCV infected individuals is clarified.Result: 1.General information comparison:(1)There was no statistical difference in gender among the three groups;(2)There were significant differences in age among the three groups(P<0.05).Continuing the comparison,it was found that there was a significant difference in age between the hepatitis group and the decompensated liver cirrhosis group,as well as between the compensated liver cirrhosis group and the decompensated liver cirrhosis group(P<0.05).There was no significant difference between the hepatitis group and the compensated liver cirrhosis group(P>0.05);(3)The proportion of infection routes in 83 patients from high to low is as follows:history of blood transfusion,unknown,history of intravenous drug addiction,history of eyebrow tattoo(tattoo history),history of unclean injection,and history of surgery;(4)Observation time: The observation time for the hepatitis group was 12-72 months,with an average of(31.46 ± 15.40)months and a median of 24 months.The observation time for the compensated liver cirrhosis group was 20-61 months,with an average of(39.23 ± 8.79)months and a median of 40 months.The observation time for the decompensated liver cirrhosis group was 14-70 months,with an average of(38.85 ±15.65)months and a median of 38 months.2.Comparison of clinical laboratory indicators:(1)At the end of the observation,there were no cases of viral quantification>12IU/ml in all three groups of patients;(2)There was a significant difference(P<0.05)in ALT,AST,AFP,and liver hardness values between patients in the hepatitis group who received SVR after treatment and those at the end of observation,and the mean value decreased.There was no significant difference(P>0.05)in ALB,DBi L,TBi L,IBi L,spleen length,spleen thickness,and portal vein width between the two groups;(3)There was a significant difference(P<0.05)in the AFP value and spleen thickness between patients in the compensatory group of liver cirrhosis who obtained SVR after treatment and those at the end of observation,with a lower mean compared to before.There was no significant difference(P>0.05)in ALB,ALT,AST,DBi L,TBi L,IBi L,liver hardness value,spleen length,and portal vein width between the two groups;(4)There was a significant difference(P<0.05)in the ALB and DBi L values between patients in the decompensated liver cirrhosis group and those at the end of observation when obtaining SVR.The mean ALB and DBi L increased compared to before,but there was no significant difference(P>0.05)in ALT,AST,TBi L,IBi L,AFP,liver hardness value,spleen length,spleen thickness,and portal vein width.Conclusion: 1.The patients in the decompensated group of liver cirrhosis are older,have a long time of infection,and their condition progresses.2.DAA drugs have long-term efficacy and definite therapeutic effects;3.Patients in the hepatitis group and liver cirrhosis compensation group can benefit in the long term after the virus is suppressed during the observation period;4.Patients in the decompensated liver cirrhosis group showed abnormal bilirubin values and imaging indicators,indicating that although the virus was suppressed,regular follow-up is still necessary.